in our study , bezafibrate in short-acting formula and long-acting formula , administered to hyperlipidaemic patients , resulted in a significant lowering of atherogenic lipids and lipoproteins ( chol.-t , ldl and vldl-chol. , apolipoprotein b and vdld-tr ) , and a marked increase in the levels of hdl , hdl2 , hdl3-chol . and apolipoprotein a with a protective action as regards vascular atherosclerotic damage .
C0023820
lipoproteins
C0003592
apolipoprotein a